Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm

Tongyuan Xue; L Elizabeth Budde

doi:10.1016/j.hoc.2020.01.006

Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm

Hematol Oncol Clin North Am. 2020 Jun;34(3):575-587. doi: 10.1016/j.hoc.2020.01.006. Epub 2020 Mar 27.

Authors

Tongyuan Xue¹, L Elizabeth Budde²

Affiliations

¹ Department of Hematology & Hematology Cell Transplantation, City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA; Department of Molecular Medicine, Beckman Research Institute, City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA; T Cell Therapeutics Research Laboratory, Beckman Research Institute, City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA; Irell & Manella Graduate School of Biological Sciences, Beckman Research Institute, City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA.
² Department of Hematology & Hematology Cell Transplantation, City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA; T Cell Therapeutics Research Laboratory, Beckman Research Institute, City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA; Irell & Manella Graduate School of Biological Sciences, Beckman Research Institute, City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA. Electronic address: ebudde@coh.org.

PMID: 32336421
DOI: 10.1016/j.hoc.2020.01.006

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, difficult-to-diagnose, highly aggressive myeloid malignancy with poor prognosis and no standard of care. The interleukin-3 receptor α, or CD123, is highly expressed in patients with myeloid malignancies, particularly acute myeloid leukemia and BPDCN. CD123 is overexpressed on leukemic stem cells compared with normal hematopoietic stem cells, suggesting CD123 as an attractive immunotherapeutic target. To date, multiple CD123-targeted therapeutic avenues have been explored to treat BPDCN and other CD123⁺ hematologic malignancies. This review summarizes immunotherapies targeting CD123 for the treatment of BPDCN and related neoplasms.

Keywords: ADC; AML; BPDCN; BsAb; CAR T; CD123; Immunotherapies.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use*
Biomarkers, Tumor
Dendritic Cells / immunology
Dendritic Cells / metabolism*
Disease Susceptibility
Drug Resistance, Neoplasm
Humans
Immune Checkpoint Inhibitors / pharmacology
Immune Checkpoint Inhibitors / therapeutic use
Immunotherapy*
Immunotherapy, Adoptive
Interleukin-3 Receptor alpha Subunit / antagonists & inhibitors*
Molecular Targeted Therapy*
Myeloproliferative Disorders / diagnosis
Myeloproliferative Disorders / etiology*
Myeloproliferative Disorders / therapy*
Receptors, Chimeric Antigen / immunology
Receptors, Chimeric Antigen / metabolism
T-Lymphocytes / immunology
T-Lymphocytes / metabolism
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Biomarkers, Tumor
IL3RA protein, human
Immune Checkpoint Inhibitors
Interleukin-3 Receptor alpha Subunit
Receptors, Chimeric Antigen